Can combination respiratory treatments, such as inhaled corticosteroids (ICS) with long‑acting β2‑agonists (LABA) or systemic steroids, cause anxiety?

Can Combination Respiratory Treatments Cause Anxiety?

Combination respiratory treatments with inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) do not directly cause anxiety as a documented adverse effect in the clinical literature or guidelines. The provided evidence focuses extensively on efficacy and safety outcomes but does not identify anxiety as a recognized side effect of these combination therapies 1, 2.

What the Evidence Shows About Side Effects

The documented adverse effects of combination ICS/LABA therapy are well-characterized and do not include anxiety:

LABA-Related Effects

• Systemic β2-agonist effects: muscle tremor and cardiac effects (palpitations, tachycardia) are the primary concerns 3
• These cardiovascular effects could potentially be misinterpreted as anxiety by patients, but they represent physiologic responses to β-agonist stimulation rather than true psychiatric symptoms
• Placebo-controlled studies show no increased risk of cardiac adverse events with LABA therapy in appropriate doses 3

ICS-Related Effects

• Local effects: oropharyngeal irritation, candidiasis
• Systemic effects: potential bone effects and cortisol suppression with high doses, but clinical relevance remains unclear 3
• No anxiety or psychiatric symptoms are documented

Combination Therapy Safety Profile

The most comprehensive safety analysis of 36,010 patients found that ICS/LABA combination therapy was not associated with increased serious adverse events compared to ICS alone 4. The focus was on asthma-related intubation, death, hospitalization, and exacerbations—not psychiatric symptoms.

Important Clinical Caveat: Systemic Corticosteroids

If systemic (oral) corticosteroids are added to the regimen for severe persistent asthma, anxiety becomes a legitimate concern. Systemic corticosteroids are well-known to cause psychiatric side effects including:

• Anxiety
• Mood changes
• Insomnia
• Psychosis (in severe cases)

The guidelines mention systemic corticosteroids for step 4-6 care in severe persistent asthma 1, 2, and these medications carry a different side effect profile than inhaled therapies.

Clinical Approach

When a patient on combination respiratory therapy reports anxiety:

1. Distinguish the medication type: Is this ICS/LABA only, or are systemic steroids involved?

   • If systemic steroids are being used, anxiety is a known side effect
   • If only inhaled therapy, anxiety is not a documented effect

2. Consider alternative explanations:

   • Palpitations or tremor from LABA being misinterpreted as anxiety
   • Underlying anxiety disorder unrelated to respiratory medications
   • Poor asthma control causing dyspnea that triggers anxiety
   • Nocturnal symptoms disrupting sleep, leading to anxiety

3. Evaluate for β-agonist overuse: Increasing SABA use (>2 days/week) suggests inadequate control and may indicate excessive sympathomimetic stimulation 2

The evidence strongly supports that standard ICS/LABA combination therapy does not cause anxiety as a direct pharmacologic effect, though systemic corticosteroids certainly can.